GlobeNewswire: AveXis, Inc. Contains the last 10 of 62 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:01:16ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/05/03/1496345/0/en/AveXis-Reports-First-Quarter-2018-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=28247AveXis Reports First Quarter 2018 Financial and Operating Results2018-05-03T20:01:00Z<![CDATA[-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions ---- AVXS-101 pre-BLA meeting with FDA is scheduled to be held in June 2018 -- CHICAGO, May 03, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the first quarter ended March 31, 2018, recent corporate highlights and upcoming milestones.]]>https://www.globenewswire.com/news-release/2018/05/01/1493658/0/en/AveXis-Provides-Update-on-Proposed-Acquisition-by-Novartis-AG.html?f=22&fvtc=4&fvtv=28247AveXis Provides Update on Proposed Acquisition by Novartis AG2018-05-01T05:07:30Z<![CDATA[CHICAGO, May 01, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the proposed acquisition of AveXis by Novartis AG (Novartis) expired at 11:59 p.m. on April 30, 2018.]]>https://www.globenewswire.com/news-release/2018/04/25/1487075/0/en/AveXis-Announces-First-Patient-Dosed-in-Phase-3-Trial-of-AVXS-101-in-Pre-Symptomatic-SMA-Types-1-2-and-3.html?f=22&fvtc=4&fvtv=28247AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 32018-04-25T12:00:00Z<![CDATA[CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first patient has been dosed in a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3 (SPRINT).]]>https://www.globenewswire.com/news-release/2018/04/24/1486622/0/en/AveXis-Presents-Initial-Data-from-Pivotal-U-S-Trial-for-SMA-Type-1-and-24-Month-Follow-Up-Data-from-Phase-1-Trial-of-AVXS-101-in-SMA-Type-1-at-the-Annual-Meeting-of-the-American-Ac.html?f=22&fvtc=4&fvtv=28247AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology2018-04-24T20:01:00Z<![CDATA[– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial –]]>https://www.globenewswire.com/news-release/2018/04/19/1481646/0/en/AveXis-to-Present-AVXS-101-Data-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology.html?f=22&fvtc=4&fvtv=28247AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology2018-04-19T12:00:00Z<![CDATA[Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial ]]>https://www.globenewswire.com/news-release/2018/04/09/1466641/0/en/AveXis-Enters-Agreement-to-be-Acquired-by-Novartis-AG-for-8-7-billion.html?f=22&fvtc=4&fvtv=28247AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion2018-04-09T04:45:00Z<![CDATA[CHICAGO, April 09, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) announced today that it has entered into an agreement and plan of merger with Novartis pursuant to which Novartis will acquire AveXis for $218 per share or a total of $8.7 billion in cash. This offer represents a premium of 88 percent to AveXis’ closing price on April 6, 2018, and a 72 percent premium to the company's 30-day volume-weighted average stock price. The transaction was unanimously approved by the Boards of Directors of both companies.]]>https://www.globenewswire.com/news-release/2018/03/27/1453606/0/en/AveXis-Gene-Therapy-Awarded-SAKIGAKE-Designation-for-Spinal-Muscular-Atrophy-Type-1.html?f=22&fvtc=4&fvtv=28247AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 12018-03-27T12:05:58Z<![CDATA[CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) awarded the company’s initial product candidate, AVXS-101, SAKIGAKE Designation (SAKIGAKE) for the treatment of spinal muscular atrophy (SMA) Type 1. The designation was based on data from the Phase 1 clinical trial of the company’s proprietary gene therapy.]]>https://www.globenewswire.com/news-release/2018/03/13/1421661/0/en/AveXis-Enters-into-Licensing-Agreement-with-Genethon.html?f=22&fvtc=4&fvtv=28247AveXis Enters into Licensing Agreement with Genethon2018-03-13T20:01:00Z<![CDATA[Includes exclusive worldwide rights to AAV9-SMN product and route of administration Includes exclusive worldwide rights to AAV9-SMN product and route of administration]]>https://www.globenewswire.com/news-release/2018/02/27/1396411/0/en/AveXis-Reports-Fourth-Quarter-and-Full-Year-2017-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=28247AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results2018-02-27T21:01:00Z<![CDATA[– On track to request pre-BLA meeting with FDA in Q2 2018 –– Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 – – Anticipates IND submissions for Rett syndrome and genetic ALS in late 2018/early 2019 –]]>https://www.globenewswire.com/news-release/2018/02/20/1361802/0/en/AveXis-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=28247AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results2018-02-20T13:00:00Z<![CDATA[Conference call and webcast on February 27 at 4:30 p.m. EST Conference call and webcast on February 27 at 4:30 p.m. EST]]>